Summit Financial LLC Sells 140 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Summit Financial LLC reduced its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,612 shares of the medical equipment provider’s stock after selling 140 shares during the quarter. Summit Financial LLC’s holdings in Intuitive Surgical were worth $1,441,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Baystate Wealth Management LLC grew its holdings in Intuitive Surgical by 150.0% during the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 45 shares during the period. MCF Advisors LLC increased its holdings in Intuitive Surgical by 108.1% in the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 40 shares in the last quarter. Able Wealth Management LLC bought a new stake in Intuitive Surgical during the 4th quarter worth approximately $28,000. Atticus Wealth Management LLC lifted its holdings in Intuitive Surgical by 85.4% during the fourth quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 41 shares in the last quarter. Finally, MeadowBrook Investment Advisors LLC bought a new position in shares of Intuitive Surgical in the fourth quarter worth approximately $30,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Down 0.6 %

ISRG traded down $2.51 during trading on Thursday, reaching $398.39. The company had a trading volume of 1,189,375 shares, compared to its average volume of 1,541,404. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $408.43. The stock has a market cap of $141.31 billion, a P/E ratio of 71.91, a PEG ratio of 5.19 and a beta of 1.39. The business has a 50 day simple moving average of $386.28 and a 200-day simple moving average of $361.18.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.00 EPS. As a group, equities research analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ISRG. StockNews.com cut shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Stifel Nicolaus increased their target price on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Truist Financial boosted their price target on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Barclays increased their price objective on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. Finally, Raymond James boosted their target price on shares of Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a report on Thursday, January 25th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $396.17.

Insider Transactions at Intuitive Surgical

In other news, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the completion of the sale, the director now directly owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the completion of the sale, the director now owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mark Brosius sold 175 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $389.16, for a total value of $68,103.00. Following the completion of the sale, the senior vice president now owns 883 shares of the company’s stock, valued at approximately $343,628.28. The disclosure for this sale can be found here. Over the last three months, insiders have sold 148,290 shares of company stock worth $57,207,154. 0.90% of the stock is currently owned by company insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.